How Long Should You Keep Cord Blood?

Cord blood stored in liquid nitrogen remains viable for at least two to three decades, and likely longer. The most direct data comes from a Spanish cord blood bank that tested units frozen for up to 29 years and found cell viability still averaging around 85 to 89 percent, depending on the processing method used.¹ So the practical question is less about whether it will still be good and more about whether keeping it makes sense for your family’s situation, your bank type, and what you’re hoping to use it for.

What the Viability Data Actually Shows

When cord blood is collected and cryopreserved, it is typically stored in liquid nitrogen at temperatures between roughly −150°C and −196°C. At those temperatures, biological activity essentially stops. Cells don’t age, they don’t deteriorate in the way tissue at room temperature would, and they don’t consume energy. A cryoprotectant, usually dimethyl sulfoxide (DMSO), is added before freezing to prevent ice crystals from destroying cells during the cooling process.²

The longest published follow-up comes from the José Carreras Cord Blood Bank in Barcelona. Researchers there tested three groups of cord blood units processed at different times and using different methods. Units that had been frozen for 29 years (processed between 1993 and 1998) showed a mean cell viability of about 89 percent. Units frozen for 25 years using a manual volume-reduction method came in around 84 percent, and units frozen for 18 years using an automated method averaged about 89 percent as well.³ The slight dip in the 25-year group probably reflects the processing technique rather than additional years of storage. That distinction matters: how the cord blood is handled before freezing appears to matter more than how long it sits in the tank afterward.

A separate analysis from the Barcelona Cord Blood Bank specifically looked at automated volume-reduced units stored for up to 20 years. Recovery of stem cells (CD34+ cells), their viability, and their ability to form colonies in lab assays showed no statistically significant decline over that period.⁴ In practical terms, a unit frozen for 20 years looked about as good as one frozen for five years when tested in the lab.

Does Storage Time Affect Transplant Success?

Lab viability is one thing, but what matters to families is whether a thawed unit will actually work in a patient. On this front, the evidence is reassuring. A study that tracked 127 transplantations using cord blood stored for up to 11 years found that the length of cryopreservation did not affect recovery of nucleated cells or stem cells after thawing. More importantly, it did not affect the time to neutrophil engraftment, which is the key early milestone that indicates the transplanted cells are taking hold and producing new blood cells.⁴ The Barcelona analysis also found no significant difference in platelet engraftment at 60 days across different storage-time groups, which led the researchers to conclude that long-term storage likely supports successful clinical transplantation.

No one has yet published data on transplants using units frozen for 29 years, because the oldest units in the world are just now approaching that age, and the opportunity to use any specific unit is rare. But based on the trajectory of the data, there is no known expiration date for properly stored cord blood. The field generally treats it as indefinitely viable so long as the liquid nitrogen storage temperature is maintained without interruption.

Why the “How Long” Question Is Really About Money

If you’ve banked cord blood privately, you’re paying an annual maintenance fee to keep it frozen. The American Academy of Pediatrics (AAP) reported that private banks typically charge a placement fee in the range of about $1,350 to $2,300 upfront, plus an annual storage fee of roughly $100 to $175.⁵ Over 20 years, that adds up to somewhere between $3,350 and $5,800, and the meter keeps running as long as you keep the unit stored. Those figures may have changed since publication, but the basic math remains: private banking is a long-term financial commitment.

A cost-effectiveness analysis in Obstetrics & Gynecology modeled the value of private banking assuming roughly $3,620 for collection and 20 years of storage. The model estimated the chance of a child needing an autologous (their own) stem cell transplant at about 0.04 percent, and the chance of a sibling needing a transplant that could use the banked cord blood at about 0.07 percent.⁶ Those probabilities are extremely low for an average family with no known genetic conditions that would make a transplant likely. For families with a child who already has a condition treatable by stem cell transplant, the calculus is entirely different and the cord blood of a new sibling can be profoundly valuable.

So when people ask “how long should I keep cord blood,” the honest answer for private banking often turns on whether you’re willing to keep paying for something with a very small chance of use. Many families pay for a few years and then quietly stop, while others keep paying indefinitely as a form of biological insurance. Neither choice is wrong, but understanding the probabilities helps frame the decision.

Public Banking Changes the Equation

If you donated your baby’s cord blood to a public bank, the storage question is out of your hands. Public banks store units for use by anyone who needs a transplant, and they bear the cost of long-term storage. Public-bank units are used far more frequently than private-bank units: the AAP cited data showing that cord blood released for clinical use was at least 30-fold greater from public banks compared to private banks.⁵ That disparity reflects both the size of the public inventory and the rarity of any individual family needing their private unit back.

Public banks have their own shelf-life considerations. They periodically assess their inventory and may discard units that don’t meet updated quality standards, that have too few cells to be useful for transplant, or that overlap with well-represented tissue types already in stock. A public bank’s decision to keep or retire a unit is based on its transplant utility, not on whether it’s biologically still good. So from the public-bank perspective, the question of how long to keep cord blood is answered by demand and inventory management rather than by viability limits.

The Cell-Dose Problem in Adult Patients

One reason cord blood storage decisions get complicated is that a single unit often doesn’t contain enough cells to transplant an adult. A cord blood collection is limited by the volume of blood in the umbilical cord and placenta, and the total number of stem cells in that volume is typically sufficient for a child but often falls short for a grown adult.⁷ This is one of the central challenges in cord blood transplantation and has driven several innovations.

Double cord blood transplants, where two units from different donors are infused together, are one workaround. Another approach being studied is expanding the stem cells in the lab before transplant. Early research showed that cord blood stem cells could be cultured outside the body for extended periods, up to 16 weeks, and expanded to numbers that would theoretically support rapid engraftment in adult patients.⁸ This line of research has progressed considerably since that early work, with several expanded cord blood products now in clinical trials or approved for use. If you’re keeping cord blood in private storage and wondering whether it will be useful for an adult family member someday, expansion technology is part of the reason the answer is more optimistic than it used to be.

Cord blood also has some biological advantages over stem cells collected from adult donors. It has been shown to have higher long-term repopulating capacity than bone marrow stem cells and is more tolerant of tissue-type mismatches between donor and recipient, which means a less-than-perfect match can still work.⁹ Worldwide, over 600,000 cord blood units are stored in banks, and the total number of unrelated cord blood transplants has reached about 30,000.

Uses Beyond Blood Cancers

Cord blood transplantation was originally developed for blood cancers like leukemia and inherited blood disorders like sickle cell disease, and those remain the most established uses. Both related and unrelated cord blood transplants have been performed with high rates of success for a range of blood disorders and metabolic storage diseases, particularly in children.¹⁰

But research is expanding into areas that could significantly broaden the reasons families might want to keep cord blood in storage. One active area is neurological conditions. A clinical study assessed whether infusing sibling cord blood into young children with cerebral palsy was safe, with early evidence suggesting it has the potential to improve motor function.¹¹ The research is early-stage, and nobody should store cord blood for 20 years on the sole assumption that cerebral palsy treatment will become routine. But these trials are one of several emerging applications, including studies in autism, neonatal brain injury, and type 1 diabetes, that could expand the utility of stored cord blood in ways that didn’t exist when most current units were banked.

This is worth factoring into your decision about how long to keep paying for private storage. The list of treatable conditions has grown since cord blood banking started in the early 1990s, and it will likely grow further. A unit that seems unnecessary today might become relevant for a use that doesn’t yet have published clinical trial results.

Cord Tissue Is a Different Conversation

Many private banks now offer to store cord tissue (the Wharton’s jelly surrounding the blood vessels in the umbilical cord) alongside the cord blood. Cord tissue contains mesenchymal stem cells, a different cell type than the blood-forming stem cells in cord blood. These mesenchymal cells are being studied for applications in orthopedics, autoimmune disease, and tissue repair.

However, the storage data for cord tissue is less mature. Research on frozen cord tissue has found mixed results: while near-equivalent maximum cell expansion could be achieved from frozen tissue, the frozen samples showed decreased initial plating efficiency and took longer to grow compared to fresh tissue.¹² This doesn’t mean the cells are useless after freezing, but it does mean the science of cord tissue cryopreservation is not as well established as it is for cord blood. If a bank is selling you cord tissue storage at an additional cost, know that the clinical applications are still largely experimental and the long-term storage track record is thinner.

What Quality Testing Does and Doesn’t Tell You

When a cord blood unit is collected and processed, banks test it for several standard quality markers: total nucleated cell count, viability, the number of viable stem cells (CD34+ cells), and whether those cells can form colonies in a lab assay. These tests confirm that the unit contains a reasonable number of living cells and that those cells can grow. What they don’t test for is the actual regenerative potency of the specific stem cells responsible for long-term engraftment.¹³

This is a gap the field is aware of. Researchers have pointed out that no cord blood units collected or transplanted so far have been tested for true stem cell quality or potency using more advanced functional assays. The standard tests are assumed to be sufficient, and in practice they have worked well enough that thousands of successful transplants have been performed. But it means that when a bank tells you your unit “passed all quality checks,” you’re getting reassurance about cell count and basic viability, not a guarantee about transplant performance. This is true regardless of how long the unit has been stored.

Practical Decision Points for Families

If you already have cord blood in private storage and you’re debating whether to keep paying, a few questions can help sharpen the decision:

Family medical history: If anyone in the immediate family has a condition currently treated with stem cell transplant (certain leukemias, lymphomas, sickle cell disease, thalassemia, severe combined immunodeficiency, and others), the value of keeping the unit is high.
Number of children: A banked unit is available not just for the child it came from but for siblings, and potentially for parents if the tissue-type match is close enough. Families with multiple children get more potential coverage from each stored unit.
Age of the unit: There is no scientific basis for discarding a unit solely because it’s been stored for a long time. The viability data supports keeping it for decades if the storage conditions are maintained. Don’t let a bank talk you into discarding a perfectly good unit because it’s “old.”
Financial strain: If the annual storage fee is a genuine burden, the very low probability of use for an average family may not justify the cost. Consider donating to a public bank at the time of collection instead, if that option is available at your delivery hospital.

Families who have already banked privately and want to stop paying generally can’t retroactively donate the unit to a public bank, because public banks have their own collection, testing, and processing standards that need to be met at the time of donation. Once you’re in private storage, your realistic options are to keep paying or to let the unit be discarded.

When Cord Blood Competes with Other Stem Cell Sources

Cord blood is one of several sources of stem cells for transplant. Bone marrow and peripheral blood stem cells collected from adult volunteer donors are the other major options, and for many patients, an unrelated adult donor with a good tissue-type match is available through registries. Cord blood’s edge lies in its tolerance for partial mismatches, its lower risk of severe graft-versus-host disease (a complication where donated cells attack the recipient’s body), and the speed with which a frozen unit can be shipped and ready for use compared to scheduling a living donor’s collection.

These advantages mean cord blood fills a specific niche. For patients from minority ethnic groups who are underrepresented in bone marrow registries, cord blood is sometimes the only viable option. For children, the cell dose in a single unit is usually sufficient. For adults, the cell-dose limitation makes it a tougher call, though the double-unit and expansion strategies mentioned earlier are closing that gap.

The existence of these alternatives is relevant to the storage question. If you’re keeping cord blood for a specific family member who might need a transplant, knowing that other donor sources exist provides some reassurance that not banking (or stopping storage) doesn’t leave that person with zero options. It just removes one option from the table.

The Unknowns That Still Matter

The science is confident that cord blood lasts decades in liquid nitrogen. But there are unknowns worth acknowledging. The longest published viability data extends to 29 years. Nobody has tested a unit frozen for 40 or 50 years, simply because organized cord blood banking hasn’t existed that long. The theoretical expectation is that cells at −196°C should remain viable essentially forever, since there is no thermal energy to drive chemical reactions that cause degradation. But theory and confirmed data are not the same thing, and the field is still accumulating evidence year by year.

Another unknown involves the evolving landscape of treatment. Gene therapy, gene editing, and other technologies may eventually reduce the need for stem cell transplants in some of the very diseases that cord blood currently treats. Sickle cell disease, for instance, now has gene therapy options that don’t require a donor at all. It’s possible that by the time a banked cord blood unit would have been needed, a better treatment will exist. That doesn’t make the storage worthless, since cord blood may find entirely new applications, but it does add uncertainty to the long-term value proposition.

Storage infrastructure itself is another factor. Private banks are businesses, and businesses can close. If a private cord blood bank goes out of business or merges with another company, your unit’s chain of custody could be disrupted. Most banks have contingency plans to transfer units to another facility, but the process isn’t always seamless. When choosing a bank, asking about their long-term contingency plans is at least as important as asking about their freezer technology.